Estudo randomizado: Monitoramento de tratamento farmacológico durante a indução de infliximabe não melhora a remissão da doença em pacientes com doenças inflamatórias crônicas imunomediadas.
7 Mai, 2021 | 10:42hEffect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (gratuito por tempo limitado)
Comentário: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly
Comentário no Twitter
Study findings do not support routine use of proactive therapeutic drug monitoring during infliximab induction for improving immune-mediated inflammatory disease remission rates https://t.co/sDslkVm3u9
— JAMA (@JAMA_current) May 5, 2021